Vireo Growth (VREOF) EPS (Weighted Average and Diluted) (2020 - 2026)
Vireo Growth's (VREOF) quarterly EPS (Weighted Average and Diluted) came in at -$0.02 in Q1 2026, little changed year-on-year from -$0.02 in Q1 2025, and down 100.0% quarter-over-quarter from -$0.01 in Q4 2025.
Vireo Growth (VREOF) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting -$0.02 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.02, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.09 (up 25.0% YoY), and the FY2025 annual result was -$0.09, up 43.75% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.02 for Q1 2026 at Vireo Growth, down from -$0.01 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.0 in Q2 2024 to a low of -$0.11 in Q1 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.04 (2023), against an average of -$0.05.
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 92.24% in 2024 and plunged 544.44% in 2025, its largest moves.
- Vireo Growth's EPS (Weighted Average and Diluted) stood at -$0.1 in 2022, then soared by 70.0% to -$0.03 in 2023, then plunged by 166.67% to -$0.08 in 2024, then jumped by 87.5% to -$0.01 in 2025, then tumbled by 100.0% to -$0.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.02 (Q1 2026), -$0.01 (Q4 2025), and -$0.03 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Vireo Growth | - | - | 59.30 Mn | -0.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.02 |
| Dec 31, 2025 | -0.01 |
| Sep 30, 2025 | -0.03 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -0.02 |
| Dec 31, 2024 | -0.08 |
| Sep 30, 2024 | -0.02 |
| Jun 30, 2024 | 0.00 |
| Mar 31, 2024 | -0.05 |
| Dec 31, 2023 | -0.03 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -0.06 |
| Mar 31, 2023 | -0.07 |
| Dec 31, 2022 | -0.10 |
| Sep 30, 2022 | -0.07 |
| Jun 30, 2022 | -0.05 |
| Mar 31, 2022 | -0.11 |
| Dec 31, 2021 | -0.10 |
| Sep 30, 2021 | -0.05 |
| Jun 30, 2021 | -0.06 |